BioMarin (NASDAQ: BMRN) CFO has 2,117 shares withheld for tax

Rhea-AI Filing Summary

BioMarin Pharmaceutical EVP and CFO Brian Mueller reported a tax-related share disposition. On March 17, 2026, 2,117 shares of common stock were withheld at $56.05 per share to cover tax obligations. After this transaction, he directly holds 123,314 common shares, indicating a routine, non–market sale event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mueller Brian

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		F		2,117	D	$56.05	123,314	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BioMarin (BMRN) CFO Brian Mueller report in this Form 4?

Brian Mueller reported a tax-related disposition of company stock. On March 17, 2026, 2,117 BioMarin common shares were withheld at $56.05 each to satisfy tax liabilities, with no open-market buying or selling activity disclosed in this filing.

How many BioMarin (BMRN) shares were withheld for Brian Mueller’s taxes?

The Form 4 shows 2,117 BioMarin common shares were withheld. These shares were valued at $56.05 per share and used to cover tax obligations, reflecting an administrative tax-withholding event rather than a discretionary open-market stock sale by the executive.

How many BioMarin (BMRN) shares does CFO Brian Mueller hold after this transaction?

After the tax-withholding transaction, Brian Mueller directly holds 123,314 BioMarin common shares. This indicates that the 2,117-share disposition is small relative to his remaining position, consistent with routine equity compensation and associated tax payments.

Was the BioMarin (BMRN) CFO’s Form 4 transaction an open-market stock sale?

No, the transaction is classified as a tax-withholding disposition. Shares were delivered at $56.05 each to cover tax liabilities, using code F on the Form 4, and do not represent an open-market sale decision by the BioMarin chief financial officer.

What does transaction code F mean in the BioMarin (BMRN) CFO Form 4?

Transaction code F means shares were used to pay exercise price or tax liabilities. In this case, 2,117 BioMarin shares were withheld at $56.05 each for tax obligations, reflecting a mechanical compensation-related event rather than a voluntary buy or sell.

Does the BioMarin (BMRN) Form 4 show any stock purchases or sales by the CFO?

The filing does not show open-market purchases or sales by the CFO. It reports only a tax-withholding disposition of 2,117 shares at $56.05 each, leaving him with 123,314 directly held BioMarin common shares after the transaction.